Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To optimize the safety and efficacy of chronic administration of idelalisib in subjects with follicular lymphoma (FL) who are randomized to treatment with idelalisib at 150 mg twice daily (BID) or 100 mg BID To evaluate the overall safety profile of idelalisib To evaluate the overall response rate (ORR) by Week 24
Critère d'inclusion
- Follicular lymphoma